FzioMed Launches New Laresse™ Dermal Filler in Europe

SAN LUIS OBISPO, California – July 13, 2006 – FzioMed, Inc. announced today the European Union launch of Laresse™ Dermal Filler, the first ultra-smooth, non-permanent filler created from the company’s patented polymer science. Laresse is a revolutionary new product for the correction of facial soft tissue contour deficiencies such as wrinkles and lines caused by sun exposure, aging and other factors.

FzioMed recently announced the establishment of an operating subsidiary in the United Kingdom to lead the sales launch of Laresse in the UK and to expand direct sales of the product throughout Europe later this year.

Laresse is the first of a line of dermal fillers being developed by the company. The product was introduced at the recent Facial Aesthetic Conference and Exhibition (FACE) held June 24-26 in London, and at the British Association of Plastic Surgeons Summer Meeting being held this week in Sheffield, UK.

Laresse is available to medical practitioners outside the U.S. through FzioMed’s direct sales force in the United Kingdom. Go to www.laresse.com for contact information.

“All of the hyaluronic acid fillers commonly used today are derived from bacterial fermentation or animal by-products, and they have to be chemically cross-linked in order to last in the skin,” said Richard Berg, Ph.D., FzioMed Vice President of Research and Chief Science Officer. “Laresse is not made from HA so it has no bacterial or animal components, no cross-linking chemicals, and no gel particles. It’s a pure, ultra-smooth, gel that can be used to shape facial contours and reduce the appearance of lines and wrinkles.”

“This launch is ground-breaking for FzioMed and for the dermal filler industry,” said John Krelle, FzioMed President and Chief Operating Officer. “Laresse is FzioMed’s first product entry into the European aesthetics and dermatology markets, and it is truly a next-generation product that we believe surpasses conventional technologies.”

About Laresse

Laresse Dermal Filler is a completely new development in dermal fillers based on FzioMed’s patented science. The smooth, easy-flowing gel is composed of pure, absorbable medical polymers that have a long history of safe use in pharmaceutical, medical device, and nutritional products. Laresse is long lasting but non-permanent and is the first filler without many of the drawbacks of hyaluronic acid and collagen fillers. Laresse is not manufactured from either bacterial or animal sources and it is not chemically cross-linked. Plans for a U.S. clinical trial with Laresse are underway.

About FzioMed

FzioMed is a privately held medical company developing and commercializing absorbable biomaterials based on the company’s patented Oxiplex technology. Oxiplex is an innovative absorbable polymer with uses in a variety of specialties including orthopedics, spine, gynecology, general surgery and aesthetic surgery. FzioMed products include Oxiplex/SP, the leading adhesion barrier for spine surgery currently marketed outside of the United States, Oxiplex/AP adhesion barrier for gynecologic and general surgery, and Laresse cosmetic dermal filler. FzioMed products are for investigational use only in the U.S.

FzioMed®, Oxiplex® and Laresse™ are trademarks of FzioMed, Inc.